熱門資訊> 正文
Chemomab Therapeutics报告第二季度业绩
2026-08-19 20:30
- Chemomab Therapeutics press release (CMMB): Q2 Net loss was $2.2 million, or a net loss of less than $0.01 per basic and diluted ordinary share, for the second quarter of 2026, compared to $2.1 million, or a net loss of less than $0.01 per basic and diluted ordinary share, for the second quarter of 2025.
- Cash Position: Cash, cash equivalents and short-term bank deposits were $6.7 million as of June 30, 2026, compared to $8.0 million as of March 31, 2026.
- Research and Development (R&D) Expenses: R&D expenses were $1.1 million for the second quarter of 2026, compared to $1.3 million for the second quarter of 2025.
- General and Administrative (G&A) Expenses: G&A expenses were $1.1 million for the second quarter of 2026, compared to $1.0 million for the second quarter of 2025.
More on Chemomab Therapeutics
- Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow
- Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
- Chemomab to merge with Scipher Medicine
- Seeking Alpha’s Quant Rating on Chemomab Therapeutics
- Historical earnings data for Chemomab Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
